Drug-Free, Nonsurgical Reduction of Intraocular Pressure for Four Months after Suprachoroidal Injection of Hyaluronic Acid Hydrogel.

Autor: Chae JJ; School of Chemical and Biomolecular Engineering Georgia Institute of Technology Atlanta GA 30332 USA., Jung JH; School of Chemical and Biomolecular Engineering Georgia Institute of Technology Atlanta GA 30332 USA.; Department of Pharmaceutical Engineering Dankook University Cheonan 16890 South Korea., Zhu W; Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University Georgia Institute of Technology Atlanta GA 30332 USA.; Department of Pharmacology School of Pharmacy Qingdao University Qingdao 266021 China., Gerberich BG; Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University Georgia Institute of Technology Atlanta GA 30332 USA., Bahrani Fard MR; George W. Woodruff School of Mechanical Engineering Georgia Institute of Technology Atlanta GA 30332 USA., Grossniklaus HE; Department of Ophthalmology Emory University School of Medicine Atlanta GA 30322 USA., Ethier CR; Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University Georgia Institute of Technology Atlanta GA 30332 USA.; George W. Woodruff School of Mechanical Engineering Georgia Institute of Technology Atlanta GA 30332 USA., Prausnitz MR; School of Chemical and Biomolecular Engineering Georgia Institute of Technology Atlanta GA 30332 USA.; Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University Georgia Institute of Technology Atlanta GA 30332 USA.
Jazyk: angličtina
Zdroj: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2020 Dec 07; Vol. 8 (2), pp. 2001908. Date of Electronic Publication: 2020 Dec 07 (Print Publication: 2021).
DOI: 10.1002/advs.202001908
Abstrakt: Glaucoma is the leading cause of irreversible blindness. Current treatments use drugs or surgery to reduce intraocular pressure (IOP). In this study, a drug-free, nonsurgical method is developed that lowers IOP for 4 months without requiring daily patient adherence. The approach involves expanding the suprachoroidal space (SCS) of the eye with an in situ-forming hydrogel injected using a microneedle. This study tests the hypothesis that SCS expansion increases the drainage of aqueous humor from the eye via the unconventional pathway, which thereby lowers IOP. SCS injection of a commercial hyaluronic acid (HA) hydrogel reduces the IOP of normotensive rabbits for more than 1 month and an optimized HA hydrogel formulation enables IOP reduction for 4 months. Safety assessment by clinical ophthalmic examinations indicate the treatment is well tolerated. Histopathology shows minor hemorrhage and fibrosis at the site of injection. Further analysis by ultrasound biomicroscopy demonstrates a strong correlation of IOP reduction with SCS expansion. Outflow facility measurements show no difference in pressure-dependent outflow by the conventional pathway between treated and untreated eyes, supporting the hypothesis. In conclusion, SCS expansion with an in situ-forming hydrogel can enable extended IOP reduction for treating ocular hypertension and glaucoma without drugs or surgery.
Competing Interests: M.R.P. serves as a consultant to companies, is a founding shareholder of companies, and is an inventor on patents licensed to companies developing microneedle‐based products (Clearside Biomedical). These potential conflicts of interest have been disclosed and are managed by Georgia Tech. J.J.C., J.H.J., C.R.E., and M.R.P. are listed as co‐inventors on an IP filing related to the above study.
(© 2020 The Authors. Published by Wiley‐VCH GmbH.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje